BOLDEN THERAPEUTICS RECEIVES $497,500 SBIR GRANT FROM THE NATIONAL INSTITUTE ON AGING TO SUPPORT DEVELOPMENT OF ANTISENSE OLIGONUCLEOTIDES TO PROMOTE NEUROGENESIS
CAMBRIDGE, Mass., June 29, 2022 /PRNewswire/ — Bolden Therapeutics, Inc., a biotechnology company developing first-in-class therapeutics to promote…